EUVIMEDEUVIMED entdecken
Crossref

TROP-2 expression in vulvar squamous cell carcinoma (VSCC) – correlation to molecular subtype

L-C Horn, GG R Hiller, C B Gilks, M Alfaraidi, L Hoang, B Wolf, A-K Höhn

Geburtshilfe und Frauenheilkunde · 01.06.2026 · 86 (06) · e39

DOI: 10.1055/s-0046-1823719 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Geburtshilfe und Frauenheilkunde, erschienen am 01.06.2026. Verfasst von L-C Horn und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Trophoblast Cell Surface Antigen 2 (TROP-2) is associated with invasiveness and tumor progression in several malignancies. Strong TROP-2-expression is associated with poor prognosis in cervical carcinoma. Recently, TROP-2 was identified as a target protein for treatment of solid tumors using antibody-drug conjugates (ADC). There are no details about the expression profiles of TROP-2 in vulval cancer (VCX).

Methods

55 cases of squamous cell carcinomas oft he vulva were immunohistochemically analysed for TROP-2 expressio using a H-score. The staining intensity (SI) was score das negative (0), weak (1), moderate (2) and strong (3). The percentage of positive stained tumor cells was calculated as 0 (complete negative staining of tumor cells), 1 (1-10% positive stained tumor cells), 2 (11-50%) and 3 (51-100%). Overall staining results were calculated by SI x percentage staining score as follows: negative (core 0),+(scores 1;2;3),++(scores 4-6) and+++(score 7-9) as previously described. Overall staining scores were compared to the molecular subtypes of vulval carcinoma, defining p16+ve/p53wt, p16-ve/p53mut and p16-ve/p53wt VCX. Staining evaluation of TROP-2 was blinded to the molecular subtype.

Results

All cases were positive for TROP-2 (7 cases+, 31 cases++and 17 cases+++) p16+ve/p53wt 16 cases mean value h-score 7,25 p16-ve/p53mut 31 cases mean value h-score 6,44 p16-ve/p53wt 2 cases mean value h-score 4 Conclusion It has been shown that the antibody drug conjugate (ADC) topoisomerase-1-inhibitor irinotecan, coupled via a linker to a humanised IgG-1ntibody hRS7 binding to TROP-2 (i.e. sacitumzumab) represents an effective treatment approach to several carcinoma types. Virtually all examined VCX showed at least weak staining for TROP-2 within the tumor cells. So, TROP-2 may represent a potential target for ADC in vulval cancer. There are no differences of TROP-2 expression within the different molecular subtypes of VCX. Publication History Article published online: 10 June 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Zitieren

APA

Horn, L., Hiller, G. R., Gilks, C. B., Alfaraidi, M., Hoang, L., Wolf, B., & Höhn, A. (2026). TROP-2 expression in vulvar squamous cell carcinoma (VSCC) – correlation to molecular subtype. Geburtshilfe und Frauenheilkunde, 86(06), e39. https://doi.org/10.1055/s-0046-1823719

Vancouver

Horn L, Hiller GR, Gilks CB, Alfaraidi M, Hoang L, Wolf B, et al. TROP-2 expression in vulvar squamous cell carcinoma (VSCC) – correlation to molecular subtype. Geburtshilfe und Frauenheilkunde. 2026;86(06):e39. doi:10.1055/s-0046-1823719

BibTeX
@article{Horn2026,
  author = {Horn, L-C and Hiller, GG R and Gilks, C B and Alfaraidi, M and Hoang, L and Wolf, B and Höhn, A-K},
  title = {TROP-2 expression in vulvar squamous cell carcinoma (VSCC) – correlation to molecular subtype},
  journal = {Geburtshilfe und Frauenheilkunde},
  year = {2026},
  volume = {86},
  number = {06},
  pages = {e39},
  doi = {10.1055/s-0046-1823719}
}
Kostenlos starten →